112 related articles for article (PubMed ID: 11841558)
1. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
Zaki MH; Wysocka M; Everetts SE; Wang KS; French LE; Ritz J; Rook AH
J Invest Dermatol; 2002 Feb; 118(2):366-71. PubMed ID: 11841558
[TBL] [Abstract][Full Text] [Related]
2. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
4. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.
Wysocka M; Newton S; Benoit BM; Introcaso C; Hancock AS; Chehimi J; Richardson SK; Gelfand JM; Montaner LJ; Rook AH
Clin Lymphoma Myeloma; 2007 Sep; 7(8):524-34. PubMed ID: 18021470
[TBL] [Abstract][Full Text] [Related]
5. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.
Rook AH; Kubin M; Cassin M; Vonderheid EC; Vowels BR; Wolfe JT; Wolf SF; Singh A; Trinchieri G; Lessin SR
J Immunol; 1995 Feb; 154(3):1491-8. PubMed ID: 7822812
[TBL] [Abstract][Full Text] [Related]
6. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma.
Rook AH; Kubin M; Fox FE; Niu Z; Cassin M; Vowels BR; Gottleib SL; Vonderheid EC; Lessin SR; Trinchieri G
Ann N Y Acad Sci; 1996 Oct; 795():310-8. PubMed ID: 8958942
[TBL] [Abstract][Full Text] [Related]
7. Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells.
Fox FE; Kubin M; Cassin M; Niu Z; Trinchieri G; Cooper KD; Rook AH
J Interferon Cytokine Res; 1999 Apr; 19(4):407-15. PubMed ID: 10334392
[TBL] [Abstract][Full Text] [Related]
8. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of IL-7 and IL-12 on human T cell activation.
Mehrotra PT; Grant AJ; Siegel JP
J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
[TBL] [Abstract][Full Text] [Related]
10. Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines.
Wysocka M; Zaki MH; French LE; Chehimi J; Shapiro M; Everetts SE; McGinnis KS; Montaner L; Rook AH
Blood; 2002 Nov; 100(9):3287-94. PubMed ID: 12384429
[TBL] [Abstract][Full Text] [Related]
11. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.
Rook AH; Gottlieb SL; Wolfe JT; Vowels BR; Sood SS; Niu Z; Lessin SR; Fox FE
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():16-20. PubMed ID: 9020930
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells.
Son YI; Dallal RM; Mailliard RB; Egawa S; Jonak ZL; Lotze MT
Cancer Res; 2001 Feb; 61(3):884-8. PubMed ID: 11221875
[TBL] [Abstract][Full Text] [Related]
14. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
15. Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.
Wysocka M; Dawany N; Benoit B; Kossenkov AV; Troxel AB; Gelfand JM; Sell MK; Showe LC; Rook AH
Leuk Lymphoma; 2011 Oct; 52(10):1970-9. PubMed ID: 21942329
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis.
Echchakir H; Bagot M; Dorothée G; Martinvalet D; Le Gouvello S; Boumsell L; Chouaib S; Bensussan A; Mami-Chouaib F
J Invest Dermatol; 2000 Jul; 115(1):74-80. PubMed ID: 10886511
[TBL] [Abstract][Full Text] [Related]
17. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro.
Ghoneum M; Jewett A
Cancer Detect Prev; 2000; 24(4):314-24. PubMed ID: 11059563
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12-responding asialoGM1+CD8+ central memory-type T cells as precursor cells for interferon-gamma-producing killer T cells.
Kosaka A; Lee U; Wakita D; Matsubara N; Togashi Y; Nishimura S; Kitamura H; Nishimura T
Cancer Sci; 2006 Nov; 97(11):1236-41. PubMed ID: 16952305
[TBL] [Abstract][Full Text] [Related]
19. Th1-mediated intestinal inflammation in Crohn's disease may be induced by activation of lamina propria lymphocytes through synergistic stimulation of interleukin-12 and interleukin-18 without T cell receptor engagement.
Okazawa A; Kanai T; Watanabe M; Yamazaki M; Inoue N; Ikeda M; Kurimoto M; Ishii H; Hibi T
Am J Gastroenterol; 2002 Dec; 97(12):3108-17. PubMed ID: 12492197
[TBL] [Abstract][Full Text] [Related]
20. Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome.
Abrams JT; Ghosh SK; DeFreitas E
Cancer Res; 1993 Nov; 53(22):5501-6. PubMed ID: 8221690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
